person · Reporting owner
Averill Madison Master Fund, Ltd.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Benitec Biopharma Inc.BNTC · Entity 5596 | Director · 10% owner | December 23, 2025 | December 30, 2025 |
| Veradermics, IncMANE · Entity 1907 | Director | August 19, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Benitec Biopharma Inc.
Report date December 23, 2025 · Filed December 30, 2025
Jointly reported with MONTANOVA CAPITAL, LLC, Cowen Aaron, Averill Master Fund, Ltd.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 9,620,075 |
Reported balance
After 2025-12-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-12-23 · Purchase · Acquired 42,600 · Balance 9,620,075 F2: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 1,834,053 |
Reported balance
After 2025-12-23 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-12-23 · Purchase · Acquired 7,400 · Balance 1,834,053 F3: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 9,634,395 |
Reported balance
After 2025-12-26 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-12-26 · Purchase · Acquired 14,320 · Balance 9,634,395 F4: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 1,836,569 |
Reported balance
After 2025-12-26 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2025-12-26 · Purchase · Acquired 2,516 · Balance 1,836,569 F5: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 9,700,195 |
Reported balance
After 2025-12-29 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2025-12-29 · Purchase · Acquired 65,800 · Balance 9,700,195 F6: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 1,848,156 |
Reported balance
After 2025-12-29 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2025-12-29 · Purchase · Acquired 11,587 · Balance 1,848,156 F7: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
Filing footnotes · ownership attribution and instrument terms
F1: Notes are included on Exhibit 99.1.
F2: Notes are included on Exhibit 99.1.
F3: Notes are included on Exhibit 99.1.
F4: Notes are included on Exhibit 99.1.
F5: Notes are included on Exhibit 99.1.
F6: Notes are included on Exhibit 99.1.
F7: Notes are included on Exhibit 99.1.
Veradermics, Inc
Report date August 19, 2026 · Filed August 21, 2026
Jointly reported with MONTANOVA CAPITAL, LLC, Cowen Aaron, Averill Master Fund, Ltd.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, par value $0.00001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 2,957,937 |
Reported balance
After 2026-08-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-08-19 · Sale · Disposed 690,601 · Balance 2,957,937 F2: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.00001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 461,033 |
Reported balance
After 2026-08-19 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-08-19 · Sale · Disposed 59,399 · Balance 461,033 F3: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.00001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 3,106,937 |
Reported balance
After 2026-08-20 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-08-20 · Other · Acquired 149,000 · Balance 3,106,937 F4: Notes are included on Exhibit 99.1. F6: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.00001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 612,033 |
Reported balance
After 2026-08-20 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-08-20 · Other · Acquired 151,000 · Balance 612,033 F5: Notes are included on Exhibit 99.1. F6: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Pre-Funded WarrantsSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-08-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-20 · Other · Disposed 149,000 · Balance 0 F6: Notes are included on Exhibit 99.1. F4: Notes are included on Exhibit 99.1. F7: Notes are included on Exhibit 99.1. F8: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Pre-Funded WarrantsSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-08-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-20 · Other · Disposed 151,000 · Balance 0 F6: Notes are included on Exhibit 99.1. F5: Notes are included on Exhibit 99.1. F7: Notes are included on Exhibit 99.1. F8: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
Filing footnotes · ownership attribution and instrument terms
F1: Notes are included on Exhibit 99.1.
F2: Notes are included on Exhibit 99.1.
F3: Notes are included on Exhibit 99.1.
F4: Notes are included on Exhibit 99.1.
F5: Notes are included on Exhibit 99.1.
F6: Notes are included on Exhibit 99.1.
F7: Notes are included on Exhibit 99.1.
F8: Notes are included on Exhibit 99.1.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 23, 2024 Filed Dec 26, 2024 21:28 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 24,360 | $10.98 | $267,472.80 |
DisclosureSEC source: 0000899140-24-001385 · form4.xml · nonDerivative · entry 1 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,981,725 F2 · shares: Notes are included on Exhibit 99.1. F2 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:36 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 4,810 | $9.60 | $46,176.00 |
DisclosureSEC source: 0000899140-24-001318 · form4.xml · nonDerivative · entry 2 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 955,124 F3 · shares: Notes are included on Exhibit 99.1. F3 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:36 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 37,190 | $9.60 | $357,024.00 |
DisclosureSEC source: 0000899140-24-001318 · form4.xml · nonDerivative · entry 1 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,957,365 F2 · shares: Notes are included on Exhibit 99.1. F2 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| November 20, 2024 Filed Nov 21, 2024 21:24 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 3,076 | $10.22 | $31,436.72 |
DisclosureSEC source: 0000899140-24-001299 · form4.xml · nonDerivative · entry 4 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 950,314 F5 · shares: Notes are included on Exhibit 99.1. F5 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F5 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| November 20, 2024 Filed Nov 21, 2024 21:24 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 24,360 | $10.22 | $248,959.20 |
DisclosureSEC source: 0000899140-24-001299 · form4.xml · nonDerivative · entry 3 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,920,175 F4 · shares: Notes are included on Exhibit 99.1. F4 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F4 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| November 19, 2024 Filed Nov 21, 2024 21:24 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 1,570 | $9.73 | $15,276.10 |
DisclosureSEC source: 0000899140-24-001299 · form4.xml · nonDerivative · entry 2 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 947,238 F3 · shares: Notes are included on Exhibit 99.1. F3 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| November 19, 2024 Filed Nov 21, 2024 21:24 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 12,430 | $9.73 | $120,943.90 |
DisclosureSEC source: 0000899140-24-001299 · form4.xml · nonDerivative · entry 1 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,895,815 F2 · shares: Notes are included on Exhibit 99.1. F2 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 21:17 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | OtherPre-Funded Warrants · Derivative | 148,210 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899140-24-001042 · form4.xml · derivative · entry 10 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 428,137 Underlying: Common Stock · 576,347 shares Expires not disclosed F7 · derivative.expiration_date: Notes are included on Exhibit 99.1. F6 · derivative.underlying_shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F6 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 21:17 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | OtherCommon Warrants · Derivative | 576,347 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0000899140-24-001042 · form4.xml · derivative · entry 9 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 576,347 shares Expires 2028-08-11 F5 · derivative.underlying_shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F5 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 21:17 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | OtherPre-Funded Warrants · Derivative | 1,219,970 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899140-24-001042 · form4.xml · derivative · entry 8 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,385,030 Underlying: Common Stock · 4,605,000 shares Expires not disclosed F7 · derivative.expiration_date: Notes are included on Exhibit 99.1. F4 · derivative.underlying_shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F4 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 21:17 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | OtherCommon Warrants · Derivative | 4,605,000 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0000899140-24-001042 · form4.xml · derivative · entry 7 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 4,605,000 shares Expires 2028-08-11 F3 · derivative.underlying_shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 21:17 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | OtherSeries 2 Common Warrants · Derivative | 10,000,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0000899140-24-001042 · form4.xml · derivative · entry 6 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 588,236 shares Expires 2027-12-09 F2 · derivative.underlying_shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 21:17 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | OtherCommon stock, par value $0.0001 per share | 148,210 | $0.00 | $14.82 |
DisclosureSEC source: 0000899140-24-001042 · form4.xml · nonDerivative · entry 5 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 945,668 F6 · shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F6 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 21:17 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | OtherCommon stock, par value $0.0001 per share | 576,347 | $3.86 | $2,224,699.42 |
DisclosureSEC source: 0000899140-24-001042 · form4.xml · nonDerivative · entry 4 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 797,458 F5 · shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F5 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 21:17 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | OtherCommon stock, par value $0.0001 per share | 1,219,970 | $0.00 | $122.00 |
DisclosureSEC source: 0000899140-24-001042 · form4.xml · nonDerivative · entry 3 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,883,385 F4 · shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F4 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 21:17 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | OtherCommon stock, par value $0.0001 per share | 4,605,000 | $3.86 | $17,775,300.00 |
DisclosureSEC source: 0000899140-24-001042 · form4.xml · nonDerivative · entry 2 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,663,415 F3 · shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 21:17 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | OtherCommon stock, par value $0.0001 per share | 588,236 | $1.93 | $1,135,236.66 |
DisclosureSEC source: 0000899140-24-001042 · form4.xml · nonDerivative · entry 1 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,058,415 F2 · shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.